Researchers for Takeda Pharmaceuticals says that a new analysis of a year-old study of Actos demonstrates that patients with type 2 diabetes and a history of one stroke reduce their chances of a second stroke by 47 percent by taking the drug. Volunteers who added Actos to standard therapy saw the rate of second strokes drop from 10.2 percent in a placebo group to 5.6 percent. Researchers added that there was no apparent difference in stroke rates among patients who had never had a prior stroke. Actos makes the cells of patients with type 2 diabetes more sensitive to insulin, allowing a better response to their own naturally produced insulin. The new data comes from existing data drawn from a large clinical study that was completed a year ago.
- read the report on Actos from TradeArabia